Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/40485
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Aleksova J. | en |
dc.contributor.author | McArthur G. | en |
dc.contributor.author | Soldatos G. | en |
dc.contributor.author | Lau P.K.H. | en |
dc.date.accessioned | 2021-05-14T13:50:52Z | en |
dc.date.available | 2021-05-14T13:50:52Z | en |
dc.date.copyright | 2016 | en |
dc.date.created | 20161229 | en |
dc.date.issued | 2016-12-29 | en |
dc.identifier.citation | BMJ Case Reports. 2016 (no pagination), 2016. Article Number: 217454. Date of Publication: 2016. | en |
dc.identifier.issn | 1757-790X (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/40485 | en |
dc.description.abstract | Immune checkpoint inhibitors offer patients with advanced melanoma substantial improvements in survival. Unlike chemotherapy, immune checkpoint inhibitors such as ipilimumab and pembrolizumab cause unique immune-related adverse events (irAEs), including the development of endocrinopathies. We report a case of a man aged 60 years who developed diabetic ketoacidosis (DKA) following the use of pembrolizumab for the treatment of metastatic melanoma. He received four cycles of ipilimumab, before proceeding to pembrolizumab. Five weeks after initiating pembrolizumab, he presented in DKA with a pH of 7.0, bicarbonate of 7 mmol/L, blood glucose of 27 mmol/L and serum ketones of 5.9 mmol/L. Antibodies to glutamic acid decarboxylase (anti-GAD) and Islet antigen 2 (IA-2) were negative and C-peptide was low at 57 pmol/L (300-2350 pmol/L). There was no personal or family history of autoimmune conditions. Standard immunosuppression for irAEs was started using prednisolone in an attempt to salvage beta cell function but was unsuccessful. To the best of our knowledge, this is the first reported attempt at reversing pembrolizumab-induced type 1 diabetes using glucocorticoids.Copyright © 2016 BMJ Publishing Group Ltd. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | BMJ Publishing Group (E-mail: subscriptions@bmjgroup.com) | en |
dc.relation.ispartof | BMJ Case Reports | en |
dc.subject | *insulin dependent diabetes mellitus/si [Side Effect] | en |
dc.subject | insulin dependent diabetes mellitus/dt [Drug Therapy] | en |
dc.subject | insulin dependent diabetes mellitus/si [Side Effect] | en |
dc.subject | insulin resistance | en |
dc.subject | intestine obstruction | en |
dc.subject | intussusception | en |
dc.subject | male | en |
dc.subject | *metastatic melanoma/di [Diagnosis] | en |
dc.subject | *metastatic melanoma/dt [Drug Therapy] | en |
dc.subject | *metastatic melanoma/rt [Radiotherapy] | en |
dc.subject | *metastatic melanoma/su [Surgery] | en |
dc.subject | metastatic melanoma/dt [Drug Therapy] | en |
dc.subject | middle aged | en |
dc.subject | multiple cycle treatment | en |
dc.subject | nuclear magnetic resonance imaging | en |
dc.subject | polydipsia/si [Side Effect] | en |
dc.subject | polyuria/si [Side Effect] | en |
dc.subject | positron emission tomography | en |
dc.subject | priority journal | en |
dc.subject | thorax radiography | en |
dc.subject | thyroid disease | en |
dc.subject | C peptide/ec [Endogenous Compound] | en |
dc.subject | *glucocorticoid/dt [Drug Therapy] | en |
dc.subject | glucose/ec [Endogenous Compound] | en |
dc.subject | hemoglobin A1c/ec [Endogenous Compound] | en |
dc.subject | insulin/dt [Drug Therapy] | en |
dc.subject | insulin/sc [Subcutaneous Drug Administration] | en |
dc.subject | ipilimumab/dt [Drug Therapy] | en |
dc.subject | ipilimumab/iv [Intravenous Drug Administration] | en |
dc.subject | liothyronine/ec [Endogenous Compound] | en |
dc.subject | *pembrolizumab/ae [Adverse Drug Reaction] | en |
dc.subject | *pembrolizumab/dt [Drug Therapy] | en |
dc.subject | *pembrolizumab/iv [Intravenous Drug Administration] | en |
dc.subject | *prednisolone/dt [Drug Therapy] | en |
dc.subject | *prednisolone/po [Oral Drug Administration] | en |
dc.subject | protein S 100/ec [Endogenous Compound] | en |
dc.subject | thyrotropin/ec [Endogenous Compound] | en |
dc.subject | thyroxine/ec [Endogenous Compound] | en |
dc.subject | transcription factor Sox10/ec [Endogenous Compound] | en |
dc.subject | multimodality cancer therapy | en |
dc.subject | adult | en |
dc.subject | article | en |
dc.subject | case report | en |
dc.subject | computer assisted tomography | en |
dc.subject | coughing | en |
dc.subject | diabetic ketoacidosis/dt [Drug Therapy] | en |
dc.subject | diabetic ketoacidosis/si [Side Effect] | en |
dc.subject | differential diagnosis | en |
dc.subject | drug dose escalation | en |
dc.subject | drug withdrawal | en |
dc.subject | dyspnea | en |
dc.subject | hemicolectomy | en |
dc.subject | histopathology | en |
dc.subject | human | en |
dc.subject | hyperglycemia | en |
dc.subject | insulin deficiency | en |
dc.subject | *insulin dependent diabetes mellitus/dt [Drug Therapy] | en |
dc.title | Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. | en |
dc.type | Article | en |
dc.type.studyortrial | Case series or case report | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/bcr-2016-217454 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 27881588 [http://www.ncbi.nlm.nih.gov/pubmed/?term=27881588] | en |
dc.identifier.source | 613434786 | en |
dc.identifier.institution | (Aleksova) Monash Health, Clayton, VIC, Australia (Lau, Soldatos) Peter MacCallum Cancer Institute, Cancer Medicine, East Melbourne, VIC, Australia (Soldatos) Monash Centre for Health Research and Implementation, Melbourne, VIC, Australia (McArthur) Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia (McArthur) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia | en |
dc.description.address | J. Aleksova, Monash Health, Clayton, VIC, Australia. E-mail: jasnaaleksova@hotmail.com | en |
dc.subject.keyword | human | en |
dc.subject.keyword | hyperglycemia | en |
dc.subject.keyword | insulin deficiency | en |
dc.subject.keyword | *insulin dependent diabetes mellitus / *drug therapy / *side effect | en |
dc.subject.keyword | insulin dependent diabetes mellitus / drug therapy / side effect | en |
dc.subject.keyword | insulin resistance | en |
dc.subject.keyword | intestine obstruction | en |
dc.subject.keyword | intussusception | en |
dc.subject.keyword | male | en |
dc.subject.keyword | *metastatic melanoma / *diagnosis / *drug therapy / *radiotherapy / *surgery | en |
dc.subject.keyword | metastatic melanoma / drug therapy | en |
dc.subject.keyword | middle aged | en |
dc.subject.keyword | multimodality cancer therapy | en |
dc.subject.keyword | multiple cycle treatment | en |
dc.subject.keyword | nuclear magnetic resonance imaging | en |
dc.subject.keyword | polydipsia / side effect | en |
dc.subject.keyword | polyuria / side effect | en |
dc.subject.keyword | positron emission tomography | en |
dc.subject.keyword | priority journal | en |
dc.subject.keyword | computer assisted tomography | en |
dc.subject.keyword | thyroid disease | en |
dc.subject.keyword | case report | en |
dc.subject.keyword | Article | en |
dc.subject.keyword | adult | en |
dc.subject.keyword | thorax radiography | en |
dc.subject.keyword | coughing | en |
dc.subject.keyword | diabetic ketoacidosis / drug therapy / side effect | en |
dc.subject.keyword | differential diagnosis | en |
dc.subject.keyword | drug dose escalation | en |
dc.subject.keyword | drug withdrawal | en |
dc.subject.keyword | dyspnea | en |
dc.subject.keyword | hemicolectomy | en |
dc.subject.keyword | histopathology | en |
dc.relation.libraryurl | LibKey Link | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2016 Elsevier B.V., All rights reserved. | en |
dc.identifier.authoremail | Aleksova J.; jasnaaleksova@hotmail.com | en |
dc.identifier.affiliationext | (Lau, Soldatos) Peter MacCallum Cancer Institute, Cancer Medicine, East Melbourne, VIC, Australia | - |
dc.identifier.affiliationext | (McArthur) Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia | - |
dc.identifier.affiliationext | (McArthur) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia | - |
dc.identifier.affiliationmh | (Aleksova) Monash Health, Clayton, VIC, Australia | - |
dc.identifier.affiliationmh | (Soldatos) Monash Centre for Health Research and Implementation, Melbourne, VIC, Australia | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
crisitem.author.dept | Endocrinology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.